NasdaqGM:LNTHMedical Equipment
How Lower Guidance and New FDA Progress Will Impact Lantheus Holdings (LNTH) Investors
In August 2025, Lantheus Holdings announced lower financial guidance for the year, reported a sales decline for the second quarter versus the previous year, and disclosed FDA acceptance of a new drug application for its F 18 PSMA imaging agent.
Alongside earnings updates, the company unveiled a US$400 million share repurchase program and highlighted plans to expand patient access through a more efficient formulation of its leading PSMA imaging product.
We will examine how the reduced...